Skip to main content

Table 1 Numbers of patients who were randomised, survived to end of the LIPID Trial, and were included in the Genetic Cohort study (n = 4932) and events that occurred in the Genetic Cohort (shown in bold in the Table) when followed for 10 years from the end of the trial

From: Common genetic variants do not predict recurrent events in coronary heart disease patients

 

Pravastatin

Placebo

Total

Randomised

4512

4502

9014

Survived to end of RCT (mean 6.1 years)

4014

3868

7882

Consented to blood sample, high quality DNA extracted

2524

2408

4932

(LIPID Genetic cohort)

LIPID Genetic Cohort (n = 4932) followed for 10 years from end of RCT

All-cause deaths

792 (31.4%)

766 (31.8%)

1558 (31.6%)

Cardiovascular deaths

455 (18.0%)

443 (18.4%)

898 (18.2%)

Coronary heart disease deaths

368 (14.6%)

359 (14.9%)

727 (14.7%)

Cancer deaths

192 (7.6%)

183 (7.6%)

375 (7.6%)